INSIGHTS ON CLINICAL TRIAL DESIGN

• Next-Generation ADC Trials – Turning Complexity Into Execution

  As ADC science advances, operational strategy becomes critical. Learn how smarter protocol design, real-time monitoring and collaborative execution can accelerate next-generation ADC trials.

• The Triple Effect Of Community-Based Clinical Trials

  Taking trials into local communities improves access, boosts enrollment, reduces dropouts, and yields more representative data, speeding timelines and strengthening study quality.

• Factors Affecting Systemic Drug Exposure

  The increasing number of drugs on the market leads to a greater potential for DDIs. Determining the extent of the interaction and associated risks is an important safety consideration.

• Real-World Data Has Real Impact On Clinical Research

  The ultimate goal of using real-world data (RWD) in clinical research is to ensure a patient is on the right therapy and receiving the right care at the right point in their healthcare journey.

• GA Screening: Early Detection For Future Trial Recruitment

  4/9/2026

  Community-based screenings identify undiagnosed eye disease at high rates, creating a scalable, high-trust pathway for early intervention and improved clinical research recruitment.

• From Data To Decisions: Accelerating Clinical Development In The AI Era

  7/10/2026

  AI and connected data are reducing delays and complexity in clinical development — when paired with strong data foundations, smarter workflows, and human‑centered change.

• Balancing Patient Centricity With Complexity In Cancer Trials

  10/28/2025

  By bringing clinical research closer to where patients live and receive care, sponsors and CROs can expand reach, reduce travel burdens, and engage populations historically underrepresented in cancer studies.

• How Pharmacometrics Informs Dose Selection And Biomarker Decisions

  6/10/2026

  Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

• Early Detection vs. Overdiagnosis: The ctDNA Screening Paradox

  6/4/2026

  Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.